Potent Anti-Cancer Activity of Benzo[d]Thiazole-Isatin Conjugates: Induces S Phase Arrest and Cell Necrosis in A549...

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Developing novel molecules is crucial for overcoming limitations in current cancer therapeutics.
• Evolving cancer characteristics necessitate continuous research into new therapeutic agents.
• Minimizing side effects and advancing scientific knowledge are key drivers in cancer drug discovery.

Purpose of the Study:

• To synthesize and evaluate a series of novel benzo[d]thiazole-isatin conjugates for anti-cancer potential.
• To assess the antiproliferative and cytotoxic activities of these compounds against various cancer cell lines.
• To investigate the mechanism of action and kinase binding affinities of promising derivatives.

Main Methods:

• Multi-step synthesis of benzo[d]thiazole-isatin conjugates (6a-6m) with high yields.
• In vitro antiproliferative and cytotoxicity assays against A549, HePG2, MDA-MB-231, and SGC7901 cell lines.
• Mechanism of action studies including cell cycle arrest and necrosis induction, alongside binding affinity assays for EGFR and CDK2.

Main Results:

• Successful synthesis of 13 novel benzo[d]thiazole-isatin conjugates with yields exceeding 90%.
• Compounds demonstrated significant antiproliferative and cytotoxic effects, comparable to the tyrosine kinase inhibitor (TKI) sunitinib.
• Compound 6g induced S-phase arrest in A549 and HepG2 cells, caused necrosis in HepG2 cells, and exhibited superior binding affinity to EGFR and CDK2 compared to gefitinib and roscovitine, respectively.

Conclusions:

• The synthesized benzo[d]thiazole-isatin conjugates represent a promising new class of anti-cancer agents.
• Compound 6g shows significant potential as an anti-cancer therapeutic due to its efficacy and specific mechanism of action.
• Further investigation into these compounds could lead to the development of novel targeted cancer therapies.